Back to dashboard
All PlansCoverageLow impact

Genetic Testing for Duchenne and Becker Muscular Dystrophy

Blue Cross & Blue Shield of Mississippi·MS · Neurology, Pediatrics, Family Medicine +2 more·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

This policy establishes coverage criteria for genetic testing for Duchenne and Becker muscular dystrophy, including molecular testing of the DMD gene to diagnose dystrophinopathies and identify female carriers at risk.

Action Required

Action needed
Review policy A.2.04.86 to understand coverage criteria for DMD/BMD genetic testing. Ensure proper documentation of clinical symptoms (muscle weakness, elevated creatine kinase levels, family history) when ordering genetic testing for dystrophinopathies to support medical necessity.

Related policy hubs